

ATTORNEY'S DOCKET NUMBER
9403-2

TRANSMITTAL LETTER TO THE UNITED

STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371U.S.
APPLICATION NO. (If known, see 37 C.F.R. 1.5)

C9/367629

EXPRESS MAIL NO.
EL262457241US

INTERNATIONAL APPLICATION NO.

INTERNATIONAL FILING DATE

PRIORITY DATE CLAIMED

PCT/US98/16383

6 August 1998

7 August 1997

TITLE OF INVENTION: DIALYSIS SOLUTIONS CONTAINING WATER SOLUBLE VITAMINS AND NUTRIENTS

APPLICANT(S) FOR DO/EO/US GUPTA, Ajay

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
 2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
 3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371 (b) and PCT Articles 22 and 39(1).
 4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
 5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
 6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
 7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
 8. ☒ Amendments to the claims of the International Application under PCT Article 34.
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
 9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
 10. ☒ An unsigned oath or declaration of the inventors. (35 U.S.C. 371 (c)(4)).
 11. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).
- Items 12. to 16. below concern other document(s) or information included:
12. ☐ An information Disclosure Statement under 37 CFR 1.97 and 1.98.
 13. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
 14. ☒ A FIRST preliminary amendment.
☐ A SECOND or SUBSEQUENT preliminary amendment.
 15. ☐ A substitute specification.
 16. ☐ A change of power of attorney and/or address letter.
 17. ☒ Other items or information:
Certificate of Express Mailing Under 37 CFR 1.10

09/367629

PCT/US98/16383

9403-2

18. X The following fees are submitted:

CALCULATIONS

PTO USE ONLY

Basic National Fee (27 CFR 1.492(a)(1)-(5)):

Search Report has been prepared by the EPO or JPO \$840.00

International preliminary examination fee paid to USPTO (37 CFR 1.482)
..... \$670.00No international preliminary examination fee paid to USPTO (37 CFR 1.482)
but international search fee paid to USPTO (37 CFR 1.445(a)(2)). \$760.00Neither international preliminary examination fee (37 CFR 1.482) nor
international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$970.00International preliminary examination fee paid to USPTO (37 CFR 1.482)
and all claims satisfied provisions of PCT Article 33(2)-(4) \$ 96.00**ENTER APPROPRIATE BASIC FEE AMOUNT =**

\$ 670.00

Surcharge of \$130.00 for furnishing the oath or declaration later than 20 X 30
months from the earliest claimed priority date (37 CFR 1.492(e)).

\$ 130.00

Claims	Number Filed	Number Extra	Rate		
Total Claims	50 - 20 =	30	x \$18.00	\$ 540.00	
Independent Claims	3 - 3 =	0	x \$78.00	\$ 0.00	
Multiple dependent claim(s) (if applicable)			+ \$260.00	\$ 0.00	

TOTAL OF ABOVE CALCULATIONS =

\$1,340.00

Reduction by 1/2 for filing by small entity, applicable. Verified Small Entity Statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).

\$ 0.00

SUBTOTAL =

\$1,340.00

Processing fee of \$130.00 for furnishing the English translation later than 20 30
months from the earliest claimed priority date (37 CFR 1.492(f)).

+ \$ 0

TOTAL NATIONAL FEE =

\$1,340.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an
appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property

+ \$ 0.00

TOTAL FEES ENCLOSED =

\$1,340.00

Amount to be
refunded

\$

charged

\$1,340.00

a. A check in the amount of \$ to cover the above fees is enclosed.b. X Please charge my Deposit Account No. 19-1135 in the amount of \$1,340.00 to cover the above fee. A duplicate copy of this sheet is enclosedc. X The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-1135 A duplicate of
this sheet is enclosed.**NOTE:** Where an appropriate time limit under 367 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to
restore the application to pending status.SEND ALL CORRESPONDENCE TO:
SEIDEL, GONDA, LAVORGNA & MONACO, P.C.
Two Penn Center Plaza
Suite 1800
Philadelphia, Pennsylvania 19102
United States of America

SIGNATURE

DANIEL A. MONACO

NAME

30,480

REGISTRATION NUMBER

09/367629

510 Rec'd PCT/PTO 19 AUG 1999

ATTORNEY DOCKET NO.: 9403-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
ACTING AS THE ELECTED OFFICE

In re application of:
Ajay Gupta

Group Art Unit: Not Yet Assigned

International Application No.:
PCT/US98/16383

Examiner: Not Yet Assigned

International Filing Date:
6 August 1998

Serial No.: Not Yet Assigned

Filed: Concurrently Herewith

For: **DIALYSIS SOLUTIONS CONTAINING WATER SOLUBLE VITAMINS
AND NUTRIENTS**

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
BOX PCT
Washington, D.C. 20231

Attention: US/DO/EO

Dear Sir:


Prior to examination of this application and before calculation of the filing fee, please amend the application, without prejudice, in accordance with the following.

Charge any fee or credit any overage associated with this preliminary amendment or the application filing to Deposit Account No. 19-1135.

CERTIFICATE OF MAILING
UNDER 37 C.F.R. 1.10

EXPRESS MAIL Mailing Label Number: EL262457241US
Date of Deposit: 19 August 1999

I hereby certify that this correspondence, along with any paper referred to as being attached or enclosed, and/or fee, is being deposited with the United States Postal Service, "EXPRESS MAIL - POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10, on the date indicated above, and addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.



Signature of person mailing paper

Lynne Webb

Type or print name of person

Please amend the application, without prejudice, in accordance with the following.

In the Claims:

39. (Amended) The dialysate solution of [one of] claim[s] 36[-38] which is a hemodialysis solution.

40. (Amended) The dialysate solution of [one of] claim[s] 36[-38] which is a peritoneal dialysis solution.


REMARKS

The above amendments are intended to remove multiple dependency within the claims prior to entry into the U.S. national phase.

Applicant hereby requests entry of the above amendment prior to calculation of the filing fee and examination.

Respectfully submitted,
AJAY GUPTA

By:



DANIEL A. MONACO
Registration No. 30,480
Seidel, Gonda, Lavorgna
& Monaco, P.C.
Suite 1800
Two Penn Center Plaza
Philadelphia, PA 19102
Telephone No.: (215) 568-8383
Facsimile No.: (215) 568-5549

Attorney for Applicant

Applicant or Patentee: Ajay Gupta
Serial or Patent No.: Not Yet Assigned
I.A. Filing Date: August 6, 1998
For: DIALYSIS SOLUTIONS CONTAINING WATER SOLUBLE VITAMINS AND NUTRIENTS

**DECLARATION CLAIMING SMALL ENTITY
STATUS (37 CFR 1.9(f) AND 1.27(b)) - INDEPENDENT INVENTOR**

As a below named inventor, I hereby declare that I qualify as an independent inventor as defined in 37 CFR 1.9(c) for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, to the Patent and Trademark Office with regard to the above-identified invention described in

- ☐ the Specification filed herewith.
☐ Application Serial No. _____ filed_____.
☒ International Application No. PCT/US98/16383 filed 6 August 1998.
☐ Patent No. _____, issued _____.

I have not assigned, granted, conveyed or licensed and am under no obligation under contract or law to assign, grant, convey or license, any rights in the invention to any person who could not be classified as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I declare under penalty of perjury that the foregoing is true and correct.

Ajay Gupta
NAME OF INVENTOR

Signature of Inventor

Date August 24, 1999

[illegible]

Dialysis solutions containing water soluble vitamins and nutrients

5

Cross-Reference to Related Applications

This application claims the benefit of United States Provisional Application Serial No. 60/055,015, filed 07 August 1997.

10

Field of the Invention

This invention generally relates to methods and compositions for hemodialysis and peritoneal dialysis. In particular, the invention relates to the use of a dialysate solution comprising at least one vitamin to improve the nutritional status of a dialysis patient.

15

Background of the Invention

A. Dialysis

20

Dialysis provides a method for supplementing or replacing renal function in patients with renal failure. Therefore, dialysis helps maintain homeostasis in patients with end stage kidney failure. Dialysis is defined as the movement of solute and water through a semipermeable membrane which separates the patient's blood from the dialysate solution. The semipermeable membrane can either be the peritoneal membrane in peritoneal dialysis patients or an artificial dialyzer membrane in hemodialysis patients. Molecules transfer

- 2 -

across this semipermeable membrane by the processes of diffusion and convection. In hemodialysis, the patient's blood is passed through an artificial kidney dialysis machine. A membrane in the machine acts as an artificial kidney for cleansing the blood. Because it is an extracorporeal system that requires special machinery, there are certain inherent disadvantages with hemodialysis.

To overcome the disadvantages associated with hemodialysis, peritoneal dialysis was developed. Peritoneal dialysis utilizes the patient's own peritoneum as a semi-permeable membrane. The peritoneum is the membranous lining of the body cavity that due to the large number of blood vessels and capillaries, is capable of acting as a natural semi-permeable membrane. In peritoneal dialysis, a dialysis solution is introduced into the peritoneal cavity utilizing a catheter. After a sufficient period of time, an exchange of solutes between the dialysate and the blood is achieved. Fluid removal is achieved by providing a suitable osmotic gradient from the blood to the dialysate to permit water outflow from the blood. The dialysis solution is then simply drained from the body cavity through the catheter.

Modern hemodialysis machines utilize a sophisticated proportioning system to mix concentrated sodium bicarbonate solution with an acid concentrate solution (containing NaCl, KCl, CaCl_2 , Na-Acetate, and glucose) and purified water. For example in the widely used Fresenius system, the ratio of acid : bicarbonate : water : total is 1 : 1.23 : 32.77 : 35. Therefore, 1 part of the concentrated bicarbonate solution is mixed with 27.5 parts of the other (acid + water), to make the final dialysate. Concentrated bicarbonate solution is either prepared from powder in the dialysis facility or is supplied by the manufacturer as a ready-made sterile solution. In making the bicarbonate concentrate, purified water is pumped from the water source by a pipe into a large tank. Sodium bicarbonate is supplied as a powder packaged in plastic bags and the contents of each bag are mixed with purified water in the tank, to make 25 gallons (94.6 liters) of bicarbonate solution. After thorough mixing with a stirrer the concentrated solution is dispensed into 20 liter plastic receptacles, that

- 3 -

are capped. The non-sterile concentrate is used within 24 hr of its preparation. In dialysis practice bicarbonate concentrate is usually prepared in 25-50 gallon quantities.

Various other compounds, in addition to salts, buffers, and carbohydrates, may be added to dialysate solutions. U.S. Patent No. 5,230,996 discloses methods and compositions for the treatment and prevention of cardiovascular disease in which ascorbate, binding inhibitors, and antioxidants are added to a hemodialysis solution. U.S. Patent No. 5,597,805 discloses the addition of dipeptides and free radical scavengers such as vitamin E, procysteine, superoxide dismutase, and chondroitin sulfate to peritoneal dialysis solutions for use during and immediately after an episode of peritonitis. Vitamin C is added to the dialysate solution in some centers in order to neutralize chloramine and prevent hemolytic anemia (Kjellstrand *et al.* (1974), *Nephron* 13:427-433), but high levels of ascorbic acid in the dialysate may predispose to oxalemia and vascular disease.

B. Vitamin Deficiencies in Dialysis Patients

Patients with chronic renal failure are at an increased risk for multiple vitamin deficiencies. Vitamin intake is often decreased in uremic patients because of anorexia and reduced food intake. Also, the diets prescribed for these patients frequently contain less than the recommended daily allowances for certain water soluble vitamins. The metabolism of folate and pyridoxine is abnormal in renal failure and many drugs have been reported to impair the metabolism and pharmacology of vitamins.

Furthermore, water soluble vitamins are removed by dialysis. In hemodialysis, some of the factors that may influence the degree of loss of a specific vitamin are the size of the vitamin molecule in relation to the pore size of the dialysis membrane, the number of pores, the blood and dialysate flow rate,

- 4 -

the duration of dialysis, the aging of the reused membrane, and the specific dialysis fluid composition. In addition, vitamins that are bound to large protein molecules are less likely to pass across the dialysis membrane. In peritoneal dialysis the peritoneum of the patient serves as the dialysis membrane and absorption plays a role in nutrient exchange. Factors influencing the flux of vitamins in peritoneal dialysis include the molalities of the different dialysates, which can affect the activity of specific exchange processes in the peritoneum, and peritonitis or sclerosis of the membrane.

C. Vitamin Supplementation in Dialysis Patients

While fat soluble vitamins are known to accumulate in uremia, deficiencies of water soluble vitamins have been reported in dialysis patients. The prescription of oral water-soluble vitamins is, therefore, a routine practice in many dialysis units.

Among the ten major dialysis centers in Australia for example, Allman reported that an oral supplement of thiamin, riboflavin, pyridoxine, ascorbic acid and nicotinamide was given in all, and folic acid was given in eight of the ten centers (Allman *et al.* (1989), *Medical Journal of Australia* 150:130-33).

On the other hand, the need for routine vitamin supplementation in dialysis patients has been questioned by some practitioners, based on the facts that hemodialysis patients are no longer on severely restricted diets, that dialysate losses may be lower than previously believed, and that recent studies in patients receiving systematic supplementation showed excessively high vitamin levels. In one study, forty-three chronic hemodialysis patients not prescribed biotin, riboflavin, or vitamin B₁₂ supplements were found to maintain normal serum levels of these vitamins for period of one year (Descombes *et al.* (1993), *Kidney International* 43:1319-28). Furthermore, despite the water solubility of thiamine,

- 5 -

riboflavin, pantothenic acid and biotin. these compounds are frequently maintained in the normal range in chronic dialysis patients. It has been postulated that the losses of these vitamins into the dialysate might be offset by the reduction in renal catabolism or urine loss in these patients. Some clinicians

5 therefore believe that no systematic supplement is indicated for biotin, riboflavin, or vitamin B₁₂ in maintenance hemodialysis patents. However, vitamin supplementation with ascorbic acid, pyridoxine, and folic acid is needed to correct vitamin deficiencies; and despite an absence of true thiamine deficiency, thiamine supplementation is needed to restore erythrocyte transketolase activity

10 in chronic dialysis patients.

D. Carnitine Deficiencies in Dialysis Patients

Carnitine is an amino acid derivative which is essential for the transport of long-chain fatty acids across the mitochondria, where fatty acids are

15 oxidized to provide energy for muscle and other cells. Signs of carnitine deficiency include muscle weakness, cardiac dysfunction, hypoglycemia, and changes in lipid profile such as elevated triglycerides. Carnitine is water soluble and not highly bound to any large molecule. Carnitine is, therefore, cleared by hemodialysis and peritoneal dialysis.

20 In a multicenter, double blind, placebo-controlled randomized clinical trial in 82 chronic hemodialysis patients it was reported that 50% of the patients randomized to receive 20 mg/kg intravenous carnitine after each hemodialysis session for a period of 6 months showed global improvement in clinical status, compared with 18% in the control group (Ahmad *et al.* (1990),

25 *Kidney International* 38:912-18). Carnitine administration resulted in improvement in intradialytic hypotension, muscle cramps, exercise capacity, a sense of well being, and possibly an increase in muscle mass. Furthermore, L-

- 6 -

carnitine deficiency in dialysis patients may promote resistance to erythropoietin action, which is corrected by L-carnitine supplementation.

5 A consensus group was convened in 1993 at Georgetown University (Washington DC) to address use of carnitine in dialysis patients. The group found that carnitine may play an important role in treating certain dialysis patients who fail to respond to standard therapy, and recommended a route and dose of administration of 20 mg/kg body weight intravenously at the end of each dialysis treatment (Consensus Group (1994), *Dialysis and Transplantation* 23:177-81).

10 Benefits to dialysis patients have been reported after the administration of both oral and intravenous carnitine. In addition, U.S. Patent Nos. 4,237,167 and 4,272,549 disclose that acyl carnitines and carnitine may be added to dialysis solutions (at levels above the concentration of free carnitine in normal serum) to alleviate asthenia and muscle weakness in chronic uremic patients.

15 Oral and intravenous supplementation of nutrients in dialysis patients present problems in terms of expense, compliance, and bioavailability. There is a need, therefore, for improved methods and compositions for the prevention and treatment of vitamin and other nutrient deficiencies in dialysis patients.

20

Summary of the Invention

The present invention relates to the discovery that vitamins, carnitine, and other nutrients may be advantageously added to dialysate solutions in order to: (1) prevent the loss of vitamins, carnitine, and other nutrients during dialysis, and (2) correct vitamin, carnitine, and other nutrient deficiencies in dialysis patients.

25

- 7 -

The invention provides a method for preventing or correcting a nutrient deficiency in a dialysis patient comprising dialysis of the patient with a dialysate solution which comprises an effective amount of at least one vitamin selected from the group consisting of folic acid, vitamin B₆, thiamine, vitamin B₁₂, and pharmaceutically acceptable salts thereof.

In some embodiments the dialysis is hemodialysis, and vitamin deficiencies may be prevented by adding at least a physiological amount of the vitamin to the dialysate solution or corrected by adding a supraphysiologic amount of the vitamin to the dialysate solution.

In some preferred hemodialysis embodiments the dialysate solution comprises: (a) up to 1500 $\mu\text{g/L}$ or up to 15 $\mu\text{g/L}$ folic acid or the equivalent molar amount of a pharmaceutically acceptable salt thereof, (b) up to 100 $\mu\text{g/L}$ or up to 10 $\mu\text{g/L}$ vitamin B₆ or the equivalent molar amount of a pharmaceutically acceptable salt thereof, (c) up to 75 $\mu\text{g/L}$ or up to 20 $\mu\text{g/L}$ thiamine or the equivalent molar amount of a pharmaceutically acceptable salt thereof, or (d) up to 60 $\mu\text{g/L}$ or up to 0.6 $\mu\text{g/L}$ vitamin B₁₂ or the equivalent molar amount of a pharmaceutically acceptable salt thereof.

In some preferred hemodialysis embodiments the dialysate solution further comprises an effective amount, preferably up to 40 mg/L or up to 15 mg/L, of vitamin C or a pharmaceutically acceptable salt thereof.

In some preferred hemodialysis embodiments the dialysate solution further comprises an effective amount, preferably up to 300 $\mu\text{mol/L}$ or up to 50 $\mu\text{mol/L}$, of carnitine or a pharmaceutically acceptable salt thereof.

In more preferred hemodialysis embodiments the dialysate solution comprises at least two nutrients or at least three nutrients selected from the group consisting of folic acid, vitamin B₆, thiamine, vitamin B₁₂, vitamin C, carnitine, and pharmaceutically acceptable salts thereof. In a most preferred embodiment

- 8 -

the dialysate solution comprises folic acid, vitamin B₆, thiamine, vitamin B₁₂, vitamin C, and carnitine, or pharmaceutically acceptable salts thereof.

In other embodiments the dialysis is peritoneal dialysis, and vitamin deficiencies may be prevented by adding at least a physiological amount of the vitamin to the dialysate solution or corrected by adding a supraphysiologic amount of the vitamin to the dialysate solution.

In some preferred peritoneal dialysis embodiments the dialysate solution comprises: (a) up to 15 mg/L folic acid or the equivalent molar amount of a pharmaceutically acceptable salt thereof, (b) up to 10 mg/L vitamin B₆ or the equivalent molar amount of a pharmaceutically acceptable salt thereof, (c) up to 7.5 mg/L thiamine or the equivalent molar amount of a pharmaceutically acceptable salt thereof, or (d) up to 1.0 mg/L vitamin B₁₂ or the equivalent molar amount of a pharmaceutically acceptable salt thereof.

In some preferred peritoneal dialysis embodiments the dialysate solution further comprises an effective amount, preferably up to 500 mg/L, of vitamin C or a pharmaceutically acceptable salt thereof.

In some preferred hemodialysis embodiments the dialysate solution further comprises an effective amount, preferably up to 1 mmol/L, of carnitine or a pharmaceutically acceptable salt thereof.

In more preferred peritoneal dialysis embodiments the dialysate solution comprises at least two nutrients or at least three nutrients selected from the group consisting of folic acid, vitamin B₆, thiamine, vitamin B₁₂, vitamin C, carnitine, and pharmaceutically acceptable salts thereof. In a most preferred embodiment the dialysate solution comprises folic acid, vitamin B₆, thiamine, vitamin B₁₂, vitamin C, and carnitine, or pharmaceutically acceptable salts thereof.

The invention also provides a dialysate solution comprising an effective amount of at least one vitamin selected from the group consisting of

- 9 -

folic acid, vitamin B₆, thiamine, vitamin B₁₂, and pharmaceutically acceptable salts thereof. In some preferred embodiments the dialysate solution further comprises an effective amount of vitamin C or a pharmaceutically acceptable salt thereof; in some preferred embodiments the dialysate solution further comprises
5 an effective amount of carnitine or a pharmaceutically acceptable salt thereof. The dialysate solution may be a hemodialysis solution or a peritoneal dialysis solution.

In more preferred embodiments the dialysate solution comprises at least two or at least three nutrients selected from the group consisting of folic acid, vitamin B₆, thiamine, vitamin B₁₂, vitamin C, carnitine, and
10 pharmaceutically acceptable salts thereof. In a most preferred embodiment the dialysate solution comprises folic acid, vitamin B₆, thiamine, vitamin B₁₂, vitamin C, and carnitine, or pharmaceutically acceptable salts thereof.

The invention further provides a vitamin concentrate solution for
15 use in a dialysate solution comprising at least one vitamin selected from the group consisting of folic acid, vitamin B₆, thiamine, vitamin B₁₂, and pharmaceutically acceptable salts thereof. In some preferred embodiments the vitamin concentrate solution further comprises vitamin C or a pharmaceutically acceptable salt thereof. In some preferred embodiments the vitamin concentrate solution further
20 comprises carnitine or a pharmaceutically acceptable salt thereof. In a more preferred embodiment the vitamin concentrate comprises at least two or at least three nutrients selected from the group consisting of folic acid, vitamin B₆, thiamine, vitamin B₁₂, vitamin C, carnitine, and pharmaceutically acceptable salts thereof. In a most preferred embodiment the vitamin concentrate solution
25 comprises folic acid, vitamin B₆, thiamine, vitamin B₁₂, vitamin C, and carnitine, or pharmaceutically acceptable salts thereof.

In some embodiments the invention provides a method for preventing or correcting a vitamin deficiency in a dialysis patient comprising dialysis of the patient with a dialysate solution which comprises an effective

- 10 -

amount of at least one vitamin selected from the group consisting of folic acid, vitamin B₆, thiamine, vitamin B₁₂, and pharmaceutically acceptable salts thereof, wherein the dialysate solution further comprises at least one iron salt.

5 In other embodiments the invention provides a method for preventing or correcting a vitamin deficiency in a dialysis patient comprising dialysis of the patient with a dialysate solution which comprises an effective amount of at least one vitamin selected from the group consisting of folic acid, vitamin B₆, thiamine, vitamin B₁₂, and pharmaceutically acceptable salts thereof, wherein the dialysate solution further comprises at least one trace element
10 selected from the group consisting of arsenic, rubidium, bromine, zinc, and pharmaceutically acceptable salts thereof.

The invention also constitutes the use of at least one vitamin selected from the group consisting of folic acid, vitamin B₆, thiamine, vitamin B₁₂, and pharmaceutically acceptable salts thereof for the preparation of a
15 dialysate solution.

Other aspects and advantages of the present invention are described in the following detailed description of the preferred embodiments thereof.

Detailed Description of the Invention

The present invention relates to the administration of vitamins, carnitine, and other nutrients by addition of the nutrients to a dialysate solution
20 for use in hemodialysis or peritoneal dialysis. The methods and compositions according to the invention may be adapted for the prevention or correction of nutritional deficiencies in dialysis patients.

- 11 -

A. Definitions

The following definitions, of terms used throughout the specification, are intended as an aid to understanding the scope and practice of the present invention.

5 **"Dialysis"** includes both hemodialysis and peritoneal dialysis.

 A **"dialysate solution"** is the solution used, on the opposite side of the membrane from the patient's blood, during dialysis. A **"vitamin concentrate solution for use in a dialysate solution"** is a composition of at least one vitamin or a pharmaceutically acceptable salt thereof, which has been
10 formulated such that dilution of the vitamin concentrate yields either a dialysate solution containing at least a physiological amount of the vitamin or yields a dialysate concentrate containing nutrients that upon further dilution provides the desired concentration of nutrients in the final dialysate.

 A **"physiological amount"** of a substance is the amount needed to
15 achieve a solution concentration within the range normally found in serum. A **"supraphysiologic amount"** of a substance is the amount needed to achieve a solution concentration higher than the range normally found in serum.

"Nutrient" includes vitamins, minerals, carnitine, trace elements, iron salts, and other compounds which are involved in human metabolism, and
20 includes pharmaceutically acceptable salts thereof.

"Vitamin" is a general term for a number of unrelated organic substances that are necessary for the normal metabolic functioning of the body. Vitamins may be water soluble or fat soluble, and include but are not limited to vitamin A, vitamin B₁ (thiamine), vitamin B₂ (riboflavin), vitamin B₆ (including
25 pyridoxine, pyridoxal, pyridoxamine), vitamin B₁₂ (cyanocobalmin), vitamin C (ascorbic acid), vitamin D, vitamin E, riboflavin, biotin, vitamin K, and folic acid.

- 12 -

B. Advantages of the Methods and Compositions According to the Invention

The methods and compositions according to the present invention offer many advantages to the clinician and patient alike, including an improved quality of life, improved patient compliance, cost effectiveness, a method for
5 therapeutic high dose B-vitamin therapy via the dialysate in hyperhomocysteinemia, avoidance of excessive accumulation of vitamins, and advantages in the administration of carnitine.

1. *Improved quality of life:* Dialysis patients are often required to take a number of medications on a regular basis. These include anti-
10 hypertensives, phosphate binders, iron supplements, stool softeners, vitamins and blockers of acid secretion. Dialysis patients are, therefore, often required to take 15-20 pills a day. The quality of life in dialysis patients may be improved by reducing the need for oral medications by administration of vitamins by the dialysate route during dialysis.

15 2. *Improved patient compliance:* Compliance with oral medication orders is often poor in dialysis patients, because of the large number of pills the patients are required to consume and associated gastrointestinal side effects. Administration of vitamins during dialysis avoids non-compliance with oral vitamin supplements. By using vitamin fortified dialysate, development of
20 vitamin deficiencies secondary to noncompliance with oral vitamin supplements can be avoided.

3. *Cost effectiveness:* Only a small fraction of oral vitamin supplements are absorbed and therefore the bioavailability is low. The bioavailability of vitamins in the dialysate is considerably higher and therefore
25 administration of vitamins via the dialysate is cost effective. Furthermore, L-carnitine administered via the dialysate is only a fraction of the cost of intravenous administration.

4. *A method for therapeutic high dose B-vitamin therapy via the dialysate in hyperhomocysteinemia:* Hyperhomocysteinemia is an important risk factor for coronary and cerebrovascular disease in the general population. Homocysteine is normally catabolized by the kidney and therefore plasma levels of homocysteine are elevated in dialysis patients. Recent studies have demonstrated that administration of folic acid and vitamins B6 and B12 in high doses leads to an approximately 30% reduction in plasma homocysteine levels over a period of 1-2 months (Bostom *et al.* (1996), *Kidney International* 49:147-52). Administration of high doses of these vitamins via the dialysate is cost effective due to higher bioavailability, and is also convenient for the patients.

5. *Avoidance of excessive accumulation of vitamins:* Dialysis patients are prescribed more liberal and wholesome diets nowadays, and some recent studies in dialysis patients receiving systematic supplementation have shown excessively high vitamin levels. By maintaining a dialysate concentration that approximates the optimal serum concentration of a vitamin, the risk of excessive accumulation is minimized. This is specially important since accumulation of folic acid or ascorbic acid may be associated with serious clinical effects.

Ascorbic acid is metabolized to oxalate and vitamin C overload leads to high circulating levels of oxalate. Chronic hemodialysis patients are known to have deposits of oxalate in heart, liver, periodontium, joints, blood vessel wall, and form urinary stones. Hyperoxalemia may increase soft tissue deposition of oxalate and thereby predispose to vascular disease, particularly small vessel disease with peripheral gangrene and severe neuropathy and myopathy.

Folate, particularly in large doses may correct the megaloblastic anemia of vitamin B₁₂ deficiency without altering the neurologic abnormalities of subacute combined degeneration. The neurologic manifestations may even be aggravated by folate therapy. Cobalamin deficiency can thus be masked in

patients who for one reason or the other are taking large doses of folate. Dialysis patients are at risk for neuropathies secondary to uremia and or diabetes and these can be difficult to distinguish from the neuropathic manifestations of cobalamin deficiency. Furthermore, dialysis patients have anemia due to renal failure *per se*.

5 Therefore, a clinical diagnosis of cobalamin deficiency is particularly difficult in dialysis patients and can be made more difficult by aggressive folate administration. High concentrations of folic acid can have a convulsant effect. Furthermore there is evidence to suggest that folic acid and anticonvulsant drugs may compete for absorption across the intestinal epithelial cell and therefore
10 therapeutic doses of folate orally may precipitate seizures in epileptics. Oral folic acid supplements of 350 μg daily reduce zinc absorption. Zinc deficiency is commonly present in dialysis patients and leads to altered taste and loss of appetite, thereby contributing to malnutrition and consequent morbidity and mortality. The need for oral folic acid supplements can be obviated if folate is
15 administered via the dialysate. Furthermore, precise control of serum folate levels is not possible with the current practice of oral folate administration, which results in high folate levels in the majority of patients. On the other hand serum folate levels can be clamped in the optimal range by addition of folic acid to the dialysate.

20 Pyridoxine overdose can result in ataxia and severe neuropathy and therefore should be avoided. Pyridoxine levels can be optimized by addition of pyridoxine to the dialysate.

Excessive amounts of ingested thiamine are rapidly cleared by the kidneys and there is no evidence of toxicity by oral administration in subjects
25 with normal renal function. Effects of excessive ingestion in patients with renal failure are not known.

6. *Advantages in the administration of carnitine:* Currently L-carnitine is prescribed to a minority of dialysis patients who are thought to be deficient in carnitine. Carnitine deficiency is very difficult to diagnose because

- 15 -

the symptoms and signs of carnitine deficiency such as weakness, asthenia, heart failure, etc. are nonspecific and are also common manifestations of kidney failure. Furthermore, serum levels of carnitine are a poor test of carnitine deficiency since only 5% or less of the total body carnitine is present in the serum. Muscle biopsies are diagnostic but seldom performed. Carnitine losses during dialysis and consequently deficiency of carnitine in the muscles are universally present in dialysis patients. Knowing the pitfalls of trying to diagnose and treat carnitine deficiency, it is proposed that carnitine deficiency should be prevented from developing in all dialysis patients by addition of L-carnitine to the hemodialysis and peritoneal dialysis solutions in low subtherapeutic concentrations that are equal to or below the concentration of free carnitine in normal serum.

Administration of carnitine via the dialysate appears to offer several advantages over the current methods of treatment. Oral carnitine therapy is expensive, not of proven benefit, involves taking several pills a day for patients who are already taking several different medications, and is not recommended in dialysis patients. On the other hand intravenous administration of carnitine is extremely expensive and therefore used in less than 0.1 % of the dialysis patients currently. Administration of L-carnitine via the dialysate also avoids excessive accumulation of L-carnitine. Dialysis patients are prescribed more liberal and wholesome diets nowadays, thereby increasing the amount of carnitine ingested. There is an increased risk of overaccumulation of carnitine when patients with impaired kidney function are prescribed oral, parenteral, or dialysate L-carnitine, since in subjects with normal renal function 58-65% of the administered dose is excreted in the urine. This is specially important since accumulation of L-carnitine may be associated with serious clinical effects including nausea, vomiting, abdominal cramps and diarrhea. A less frequent side-effect is body odor. Mild myasthenia manifesting as muscle weakness has been described only in uremic patients receiving carnitine. These side-effects resemble the effects of

- 16 -

underlying uremia and therefore may confuse the clinician. By maintaining a dialysate concentration that is less than or equal to the normal serum concentration of free carnitine, the risk of excessive accumulation is minimized.

C. General principles of Dialysis and Vitamin Homeostasis

5 Water soluble molecules such as folic acid, pyridoxine and carnitine diffuse from patient's blood to the dialysate and *vice versa*, depending on the concentration gradient across the semipermeable membrane. Therefore, the net egress of molecules from the blood compartment can be prevented if the concentration of the molecule in the dialysate solution is equal to its concentration
10 in the serum. This principle is used to maintain sodium, potassium, calcium, chloride, bicarbonate, and magnesium homeostasis in hemodialysis patients, by addition of these molecules to the dialysate compartment in different concentrations based on the patients' needs. In accordance with this principle, if the dialysate concentration of a freely diffusible vitamin or L-carnitine is equal
15 to the normal serum concentration the direction of net transfer will be from the dialysate to the blood compartment in a patient who is deficient in this molecule and from the blood to the dialysate compartment in a patient with vitamin overload. It should be noted that the concentration of vitamin in the dialysate should be based upon the normal serum concentration of the free and not the
20 total vitamin. This principle is useful for supplementing water soluble vitamins, carnitine and other nutrients in chronic hemodialysis or peritoneal dialysis patients, by addition of these compounds to the dialysate solutions.

D. Compositions According to the Invention

25 The present invention is directed to dialysate solutions comprising at least one vitamin selected from the group consisting of folic acid, vitamin B₆, thiamine, vitamin B₁₂, and pharmaceutically acceptable salts thereof. The skilled artisan can adapt the disclosed methods and compositions to the individual needs and the desired results in the patient being treated.

- 17 -

Different vitamin compounds and pharmaceutically acceptable salts thereof can be used in the methods and compositions according to the invention.

Sources of thiamine include thiamine disulfide, thiamine mononitrate, thiamine phosphoric acid ester chloride, thiamine phosphoric acid ester phosphate, thiamine 1,5-salt, and thiamine triphosphoric acid ester.

As a source of folic acid, folinic acid is an intermediate product in the metabolism of folic acid; the active form into which folic acid is converted in the body, ascorbic acid being a necessary cofactor in the conversion process.

Sources of vitamin B₆ include pyridoxine hydrochloride, pyridoxal 5-phosphate, pyridoxamine dihydrochloride, and pyridoxal.

Cobalamin is protein bound in blood, so losses of vitamin B₁₂ in dialysate are expected to be low in dialysis patients. However there is evidence to suggest that hemodialysis patients should be prescribed low doses of vitamin B₁₂. First, the postdialysis serum levels of vitamin B₁₂ have been found to decrease significantly during hemofiltration treatment. Second, vitamin B₁₂ intake has been found to be below the recommended daily allowance in maintenance hemodialysis patients. Third, several cases of vitamin B₁₂ deficiency have been reported in maintenance hemodialysis patients. Fourth, the losses of cobalamin with high efficiency or high flux dialysis are not known. Fifth, Long-term effects of erythropoietin treatment on cobalamin stores have not been studied. Sixth, even with normal cobalamin stores, pharmacologic doses have been shown to improve nerve conduction velocities. Last, because of its effects on folate metabolism cobalamin might be useful in lowering plasma homocysteine levels in dialysis patients. A placebo-controlled 8 week trial of 15 mg folic acid, 100 mg vitamin B₆, and 1 mg vitamin B₁₂ led to a 25-30% reduction in plasma homocysteine levels in maintenance hemodialysis patients (Bostom *et al.* (1996), *Kidney International* 49:147-52). The contribution of vitamin B12 to these results is not known. Cyanocobalamin is soluble in water and it is one purpose of this invention of add cyanocobalamin or its analogs to the dialysate for the purposes of prevention and treatment of vitamin B₁₂ deficiency.

- 18 -

Other nutrients that may be added to the dialysate solution in the methods and compositions according to the invention include L-carnitine or other isomers of carnitine, other vitamins, ferric pyrophosphate and other iron salts, and trace elements.

5 Other vitamins include vitamins A, D, E, K, riboflavin, and pantothenic acid.

Other iron salts include ferric gluconate, ferric saccharate, ferric citrate, ferric acetate, ferric chloride, ferric fluoride, ferric iodide, ferric 12-hydroxystearate, ferric stearate, ferric subsulfate, ferric glycerophosphate, ferric
10 hydroxide, ferric nitrate, ferric orthophosphate, ferric oxalate, ferric behenate, ferric-ammonium sulfate, ferric-o-phosphate, and ferric sodium oxalate.

Patients with kidney failure may be deficient in some trace elements and overloaded with others. The brains of dialysis patients are deficient in arsenic, rubidium, and bromine. One of the most striking findings
15 in dialysis patients is the decrease in rubidium content of most tissues. Dialysis patients also have decreased iron content in the heart and zinc content in the muscle. Trace elements may be added to the dialysate solution in the form of water soluble salts.

The vitamins and other nutrients can be added to different
20 components of the dialysate solution in the methods and compositions according to the invention. The vitamins and other nutrients, for example, may be added to the bicarbonate concentrate, or the acid concentrate, or may be added separately in solution or powdered form. Experimental work has shown that some vitamins are freely soluble in the bicarbonate concentrate but not the acid
25 concentrate. Other vitamins are soluble in acidic solution. Based on the specific salts of the vitamins chosen, it is possible to increase the stability of the vitamins in solution by addition of some vitamin salts that are soluble in an acidic solution to the acid concentrate and others to the bicarbonate concentrate.

When the vitamins are added to a bicarbonate concentrate, the
30 bicarbonate concentrate advantageously has a concentration that is 27.5 fold

- 19 -

higher than the desired concentration in the dialysate solution, because the bicarbonate concentrate is typically diluted 27.5-fold in the final dialysate solution. When it is considered desirable that the majority of patients in the dialysis unit receive nutrients via the dialysate the nutrient mix can be added to the large container of 50-200 liter capacity that is used to make or store bicarbonate concentrate. This would obviate the need for addition of the nutrients to individual bicarbonate containers, thereby increasing efficiency in the dialysis unit. If acetate dialysate is used the concentration of vitamins in the concentrate is advantageously 34 fold higher than the desired concentration in the dialysate solution.

Vitamins and other nutrients may be added to the dialysis solutions separately or mixed together. Again, separately or together, the ingredients may be added as dry powders or in a solution form. Any of these methods of formulating the ingredients are satisfactory for producing stable clear aqueous compositions by the process of this invention. The amount of the vitamin and other nutrients is limited only by their mutual compatibility in aqueous solutions.

For aqueous solutions containing a vitamin, the pH of the solution is advantageously adjusted to maximize solubility and stability of the compound. Experimental work suggests that an acidic pH about 4.2-4.6, preferably 4.4 may be optimal for vitamin compositions according to the invention. The pH adjustment can be accomplished by any pharmaceutically acceptable organic or inorganic base or acid. In a preferred embodiment citric acid is used. If the pH is lower, e.g. 3 to 4, the stability of certain B vitamins may be adversely affected. If the pH is too high, e.g. over 4.6, greater decomposition of the vitamin B₁ may result. When a dry powder or aqueous solution is added to the bicarbonate concentrate, the concentration of vitamins and other nutrients in the dialysate concentrate can be adjusted so that it is slightly higher than the desired concentration during dialysis in order to compensate for degradation in the alkaline environment.

30

- 20 -

E. Use of the Invention in Hemodialysis Patients

The methods and compositions according to the invention may be used for the prevention or treatment of vitamin and other nutrient deficiencies in hemodialysis patients. To prevent deficiencies, the vitamins and other nutrients
5 may be added to the dialysate solution for every dialysis session or may be added intermittently, *e.g.* once a week or once a month.

Different vitamins and nutrients are bound to different extents in plasma and this binding must be taken into consideration when practicing the invention.

10 Table 1 summarizes several principles for the basis of the invention, including suggested concentrations of compounds (vitamins and other nutrients) in the dialysate solution for the prevention and treatment of deficiencies.

Tables 2 and 3 show suggested concentrations of vitamins and carnitine in hemodialysate solutions for the prevention (Table 2) and treatment
15 (Table 3) of deficiencies.

The values suggested in Tables 1- 3 are suggested values only, and the skilled artisan will routinely tailor these concentrations to meet individual patient needs and to improve the efficiency of the dialysis unit.

TABLE 1

Principles For the Basis of the Invention

	Concentration Of Compound In The Dialysate Solution For The Purpose Of	
	<i>Prevention of deficiency by addition to dialysate with every dialysis</i>	<i>Treatment of deficiency or prevention of deficiency by adding intermittently (once a week-month)</i>
5	<i>Characteristic of the plasma protein binding</i>	
	<i>No significant protein binding</i>	equal to normal plasma level up to 10-50 fold higher than the normal plasma level
	<i>Significant binding present and free level in the plasma is known</i>	equal to normal plasma level of the free compound up to 10-50 fold higher than the normal plasma level of the free compound
10	<i>Significant binding present but the fraction bound and therefore the free level in the plasma is not known¹</i>	equal to [total normal plasma level] \div $(V_p/V_D)^2$ up to 10-50 fold higher than [total normal plasma level] \div $(V_p/V_D)^2$

15 ¹ The effects of uremia on plasma protein binding of vitamins are not known. Therefore in dialysis patients the extent of protein binding is not known for vitamins that are normally protein bound.

20 ² For vitamins that bind to plasma proteins the concentration of vitamins achieved in plasma (V_p) should exceed the vitamin concentration in the dialysate (V_D) after sufficient dialysis.

Table 2

Hemodialysis Solutions¹ for the Prevention of Vitamin and Carnitine
Deficiencies in Hemodialysis Patients

		<i>Fraction of the plasma content that is protein bound (%)²</i>	<i>Normal plasma concentration</i>	<i>Preferred concentration in the dialysate during every dialysis session for the prevention of deficiencies³</i>
	Folic acid	1. low affinity binding to albumin 2. high affinity binding to glycoproteins (<5%)	5-15 µg/L	<15 µg/L
5	Ascorbic acid (vit C)	not bound	4-15 mg/L	<15 mg/L
	Pyridoxal 5'-phosphate (vit B ₆)	albumin	3-10 µg/L	<10 µg/L
10	Thiamine	albumin	Whole blood: 20-37 µg/L Plasma ⁴ : 4-20 µg/L	<20 µg/L
	Vitamin B ₁₂	Protein bound	Serum: 0.2-0.6 µg/L	<0.6 µg/L
	Free L-carnitine	not bound	20-50 µmol/L	<50 µmol/L

¹ The concentration of the nutrients in the concentrate is proportionately higher so that upon dilution the final concentration in the dialysate solution is appropriate. For the Fresenius system, for example, the concentration of compound in bicarbonate concentrate is 27.5 times the desired concentration in the dialysate and if acetate dialysate is used the concentration of vitamins in the

- 23 -

concentrate should be 34 fold higher than the desired concentration in the dialysate.

²The binding of compounds to plasma proteins may be altered in uremia. The uremic toxins may displace some compounds from their binding sites on
5 plasma proteins (e.g. dilantin). Effects of uremia on the plasma protein binding of the above vitamins have not been examined.

³ The highest concentration of the compound in the dialysate for prevention of deficiency has been chosen as upper limit of normal serum level. However there may be chemical degradation of the vitamins in the dialysis
10 concentrate if the solution is not used immediately after the addition of the vitamins due to light sensitivity or chemical interaction between the different compounds. The concentrations of the vitamins in the concentrate may therefore be increased to compensate for this potential loss of vitamins.

⁴A fraction of the whole blood thiamine is found in the plasma. Most
15 of the thiamine in plasma may be bound to albumin (in subjects with normal kidney function).

TABLE 3

Hemodialysis Solutions¹ for the Treatment of Vitamin and Carnitine Deficiencies in Hemodialysis Patients

	Plasma concentrations reported in hemodialysis patients receiving supplementation in high doses	Preferred concentration in the dialysate for the treatment of deficiencies²	
5	Folic acid	927±575 µg/L with 15 mg folic acid daily for 8 weeks ³	15 µg/L - 1500 µg/L
	Ascorbic acid (vitamin C)	28±2 mg/L (mean±SE), Range: 15-37 mg/L, with 500 mg ascorbic acid/day for 2 weeks ⁴	up to 40 mg/L
	Pyridoxine or Pyridoxal 5'-Phosphate (vit B ₆)	45±36 µg/L with 100 mg B ₆ /day for 8 weeks ³	up to 100 µg/L
	Thiamine	Whole blood thiamine 50±12 µg/L with 600-900 mg thiamine per week ⁵	up to 75 µg/L
10	Vitamin B ₁₂	1.3±0.4 µg/L ³	up to 60 µg/L
	L-carnitine	Free carnitine 250±11 µmol/L (mean±SE) on 20 mg/Kg of L-carnitine intravenously three times a week following hemodialysis for 6 months ⁶	50-300 µmol/L

¹ Unless reported otherwise all values are predialysis values expressed as mean±SD

² It may be more convenient and feasible to add a large amount of the compound during a single dialysis session (e.g. once a week) rather than during every dialysis
 15 Therefore, these higher concentrations may also be needed for prevention when used intermittently in addition to being needed for treatment of deficiencies.

- 25 -

³ Bostom *et al.* (1996), *Kidney International* 49:147-52.

⁴ A Ponka, B Kuhlback (1983), *Acta Medica Scandinavica* 213:305-7

⁵ E Descombes, AB Hanck, G Fellay (1993), *Kidney International* 43:1319-28.

⁶ TA Golper *et al.* (1990), *Kidney International* 38:904-11.

5 F. Use of the Invention in Peritoneal Dialysis Patients

Peritoneal dialysis patients commonly use 3-10 exchanges per day depending on the type of peritoneal dialysis treatment. Addition of vitamins and other nutrients to every bag of peritoneal dialysis solution by the patient may increase the risk of contamination, thereby introducing infection leading to peritonitis. To avoid this complication drugs such as antibiotics are often administered to the patient in large supraphysiologic amounts added to the bag that dwells overnight, instead of small amounts added to every exchange. Therefore, vitamins, carnitine, and other nutrients are advantageously added in high concentrations to sporadic bags either to prevent deficiency from intradialytic loss of vitamins or to correct such a deficiency state.

EXAMPLES

The following examples illustrate the invention. These examples are illustrative only, and do not limit the scope of the invention.

EXAMPLE 1

20 **Preparation and Use of Vitamin Concentrate Solutions**

A. Preparation of a Vitamin Concentrate Solution

A vitamin concentrate solution was prepared according to the formulation shown on Table 4.

Table 4

	<i>Ingredient</i>	<i>Amount per 250 ml</i>
	Thiamine HCl	65.06 mg
	Folic acid	26.024 mg
5	Ascorbic acid	26.024 g
	Pyridoxine HCl	26.024 mg

B. Preparation of a Vitamin Concentrate Solution With Iron

A vitamin concentrate solution with iron was prepared according to the formulation shown on Table 5.

10

Table 5

	<i>Ingredient</i>	<i>Amount per 250 ml</i>
	Ferric pyrophosphate	2.750 mg
	Thiamine HCl	65.06 mg
	Folic acid	26.024 mg
15	Ascorbic acid	26.024 g
	Pyridoxine HCl	26.024 mg

C. Preparation of a Vitamin Concentrate Solution With Carnitine

L-carnitine (2.6 mmoles) is added to solutions in example 1 or 2 either as a dry powder or as a solution.

20

D. Use of a Vitamin Concentrate Solutions to Prepare a Dialysate Solution

A vitamin concentrate solution according to Example 1A, 1B, or 1C is adjusted to pH 4.4 using citric acid. The 250 ml vitamin concentrate

- 27 -

solution is added to 25 gallons (i.e., 10 ml is added per gallon) of bicarbonate concentrate for hemodialysis to make a vitamin plus bicarbonate concentrate. One part of the vitamin plus bicarbonate concentrate is diluted with 27.5 parts of acid concentrate and water (1:32.77) to prepare the dialysate solution.

5

EXAMPLE 2

Dialysis of Uremic Plasma

To determine the concentration of a vitamin or other nutrient in the dialysate that is needed to maintain the serum level in the normal range, it is important to know the plasma concentration of the freely filterable vitamin. However, uremic toxins may alter the binding of vitamins to plasma proteins. In uremic subjects, the proportion of the total plasma vitamin that is free is not known. In the following experiment uremic plasma was dialyzed against dialysate solutions containing different concentrations of vitamins, and the total plasma levels of vitamins after dialysis was measured.

Plasma obtained from a uremic subject undergoing plasmapheresis was pooled and samples were taken for estimation of baseline vitamin levels. The total volume of 2.7 liters was divided into three equal aliquots of 900 ml each. Hemodialysis was performed on each aliquot of plasma using a F-60 polysulfone dialyzer (Fresenius Inc., USA). The plasma flow rate was 350 ml/min and the dialysate flow rate was 500 ml/min.

In the first experiment, vitamins were not added to the dialysate. In the second experiment, vitamins were added to the dialysate at a concentration that was close to the upper limit of normal, to simulate the maintenance of physiologic levels. In the third experiment, vitamins were added to the dialysate at a concentration that was 10 times that in the second experiment, with the aim of achieving supratherapeutic levels. The results of the three experiments are summarized in Table 6.

Table 6

In Vitro Hemodialysis of Uremic Plasma Using Dialysate Solutions With and Without the Addition of Vitamins

Concentration of vitamin in the dialysate	Plasma concentration of the vitamin after dialysis for			Ratio of Plasma to dialysate at the end of dialysis (V_p/V_D)
	0 min (Baseline)	45 min	90 min	

Folic Acid

0 µg/L	5.8 µg/L	1.7 µg/L	3.3 µg/L	not applicable
15 µg/L	5.8 µg/L	32.2 µg/L	39.8 µg/L	2.6
150 µg/L	5.8 µg/L	256.5 µg/L	272.2 µg/L	1.8

Thiamine (B_1)

0 µg/L	17 µg/L	not done	3.6 µg/L	not applicable
60 µg/L	17 µg/L	not done	72 µg/L	1.2
600 µg/L	17 µg/L	not done	>100 µg/L	not estimated

The plasma pyridoxal 5-phosphate (PLP) concentration decreased from 5.2 µg/L to 3.1-3.7 µg/L after 90 minutes of dialysis. Addition of pyridoxine hydrochloride to the dialysate did not result in an increase in PLP concentration since the assay used is specific for esters such as PLP and does not measure pyridoxine.

It is expected that following termination of dialysis with vitamin containing dialysate there will be tissue uptake and metabolism of the vitamins, thereby leading to a progressive fall in the plasma vitamin concentration that may continue to occur till the time of the next dialysis session. Therefore, it would be desirable to attain a total plasma vitamin concentration that is close to the upper

- 29 -

limit of normal towards the end of a hemodialysis session. For the vitamins that are bound partly to plasma proteins, the total plasma level of vitamins achieved is higher than the level of the vitamins in the dialysate (see table 1). However the efficiency of diffusive transport across the dialyzer membrane is determined partly readily compared to larger compounds. Therefore dialysate vitamin concentration needs by the molecular weight of the compound. Smaller compounds cross more to be determined separately for every vitamin. The required dialysate vitamin concentration may be derived by dividing the desired plasma concentration by the plasma to dialysate vitamin gradient (V_P/V_D).

10

EXAMPLE 3

Vitamin and Carnitine Delivery Via Dialysate in a Maintenance Hemodialysis Patient With End-Stage Kidney Failure

The following example illustrates how the methods and compositions according to the invention are used in a maintenance hemodialysis patient, and is applicable to every maintenance hemodialysis patient.

A powdered mixture of vitamins and L-carnitine is available in the hemodialysis unit in an amber vial containing 1.03 milligrams folic acid, 1.3 grams ascorbic acid, 0.7 milligrams pyridoxine hydrochloride, 2 milligrams thiamine, 70 micrograms cobalamin, and 660 milligrams L-carnitine. Just prior to starting dialysis the dialysis technician empties two of these vials into a plastic container with 10 liters of a concentrated solution of sodium bicarbonate (bicarbonate concentrate). The technician rocks the container back and forth 5 times. The powder readily goes into solution and the solution turns a light orange color due to the color of folic acid. The technician starts the hemodialysis machine (Fresenius Inc., USA). The automated proportioning system in the machine mixes 1.23 parts of the bicarbonate concentrate with 1 part of a concentrated acidic solution (containing NaCl, KCl, CaCl₂, Na-acetate, and glucose) and 32.77 parts of pure water, thereby generating the final dialysate

20
25

09367629-101899

- 30 -

solution. The final dialysate solution contains 7.5 μ g folic acid, 10 mg ascorbic acid, 5 μ g pyridoxine, 15 μ g thiamine, and 4.8 mg L-carnitine per liter of solution.

The patient has end-stage kidney failure and is on maintenance hemodialysis. His blood is circulated at a rate of 450 ml/min through a F-80 polysulphone dialyzer (Fresenius Inc., USA) and dialyzed against the vitamin and L-carnitine containing dialysate flowing into the dialyzer at a rate of 800 ml/min. The patient is dialyzed for 4 hours three times a week using the same procedure for generating vitamin and L-carnitine fortified dialysate. The patient therefore does not require oral vitamin supplements which are stopped. The patient had been poorly compliant with his medications, and consequently regular dialysate vitamin supplementation leads to an improvement in his general condition. With time there is also an improvement in cardiac function, hyperhomocysteinemia and neuropathy, and a decrease in the erythropoietin requirement.

When it is considered desirable that the majority of patients in the dialysis unit receive vitamins and other nutrients via the dialysate, the vitamin and nutrient mix can be added to a large container (e.g., 50-200 liter capacity) that is used to make or store bicarbonate concentrate. This obviates the need for addition of vitamins and nutrients to individual bicarbonate containers, thereby increasing efficiency in the dialysis unit.

EXAMPLE 4

Modification of the Nutrient Mix to Meet the Special Requirements of an Individual Patient

The following example illustrates how the methods and compositions according to the invention are modified for an individual patient.

A hemodialysis patient with diabetes, hypertension, and coronary artery disease develops transient ischemic attacks. His cholesterol is found to be normal but the plasma homocysteine is twice the upper limit of normal. The

- 31 -

hyperhomocysteinemia is present despite regular administration of standard doses of folic acid and pyridoxine orally. The patient is prescribed supraphysiologic doses of oral folic acid (15 mg/day), vitamins B₆ (100 mg/day), and B₁₂ (1 mg/day). The patient, however, is non-compliant with this regimen due to associated gastrointestinal side-effects and the increased number of pills that he is required to take. The patient is therefore prescribed high doses of folic acid, B₁₂ and B₆ via the dialysate (See Table 3), leading to normalization of homocysteine levels over a period of 3 months.

EXAMPLE 5

10 Vitamin and Carnitine Supplementation Via Peritoneal Dialysis Solution

A diabetic patient receiving peritoneal dialysis has coronary artery disease, hyperhomocysteinemia, progressive peripheral sensorimotor neuropathy, diabetic gastroparesis and malnutrition. The patient does not tolerate oral medications due to gastroparesis and vomiting. The patient comes to the dialysis clinic every 3 weeks for a follow up. Upon his clinic visit the dialysis nurse adds a concentrated sterile solution of vitamins and L-carnitine containing 10 mg folic acid, 1 mg vitamin B₁₂, 500 mg vitamin C, 5 mg thiamine, 10 mg pyridoxine, and 600 μ mol of L-carnitine to a 2 liter (2L) bag of peritoneal dialysis solution. This bag is infused into the patients peritoneal cavity and patient is instructed to drain it out after 6 hours. The procedure is repeated every 3 weeks during his regular clinic visit. The patient is able to discontinue his oral vitamin supplements and with time there is improvement in his general condition, appetite, nutritional status and a decline in the plasma homocysteine levels.

All references discussed herein are incorporated by reference. One skilled in the art will readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof and, accordingly, reference should be made to the appended claims, rather than to the foregoing specification, as indicating the scope of the invention.

CLAIMS

I CLAIM

1. A method for preventing or correcting a vitamin deficiency in a dialysis patient comprising dialysis of the patient with a dialysate solution which
5 comprises an effective amount of at least one vitamin selected from the group consisting of folic acid, vitamin B₆, thiamine, vitamin B₁₂, and pharmaceutically acceptable salts thereof.
2. The method of claim 1 wherein the dialysis is hemodialysis.
3. The method of claim 2 wherein the vitamin deficiency is
10 prevented by adding at least a physiological amount of the vitamin to the dialysate solution.
4. The method of claim 2 wherein the vitamin deficiency is corrected by adding a supraphysiologic amount of the vitamin to the dialysate solution.
5. The method of claim 2 wherein the dialysate solution comprises
15 up to 1500 µg/L folic acid or the equivalent molar amount of a pharmaceutically acceptable salt thereof.
6. The method of claim 5 wherein the dialysate solution comprises up to 15 µg/L folic acid or the equivalent molar amount of a pharmaceutically
20 acceptable salt thereof.
7. The method of claim 2 wherein the dialysate solution comprises up to 100 µg/L vitamin B₆ or the equivalent molar amount of a pharmaceutically acceptable salt thereof.
8. The method of claim 7 wherein the dialysate solution comprises
25 up to 10 µg/L vitamin B₆ or the equivalent molar amount of a pharmaceutically acceptable salt thereof.

- 33 -

9. The method of claim 2 wherein the dialysate solution comprises up to 75 $\mu\text{g/L}$ thiamine or the equivalent molar amount of a pharmaceutically acceptable salt thereof.

10. The method of claim 9 wherein the dialysate solution
5 comprises up to 20 $\mu\text{g/L}$ thiamine or the equivalent molar amount of a pharmaceutically acceptable salt thereof.

11. The method of claim 2 wherein the dialysate solution comprises up to 60 $\mu\text{g/L}$ vitamin B₁₂ or the equivalent molar amount of a pharmaceutically acceptable salt thereof.

10 12. The method of claim 11 wherein the dialysate solution comprises up to 0.6 $\mu\text{g/L}$ vitamin B₁₂ or the equivalent molar amount of a pharmaceutically acceptable salt thereof.

13. The method of claim 1 wherein the dialysate solution further comprises an effective amount of vitamin C or a pharmaceutically acceptable salt
15 thereof.

14. The method of claim 13 wherein the dialysate solution comprises up to 40 mg/L vitamin C or the equivalent molar amount of a pharmaceutically acceptable salt thereof.

15. The method of claim 14 wherein the dialysate solution
20 comprises up to 15 mg/L vitamin C or the equivalent molar amount of a pharmaceutically acceptable salt thereof.

16. The method of claim 1 wherein the dialysate solution further comprises an effective amount of carnitine or a pharmaceutically acceptable salt thereof.

25 17. The method of claim 16 wherein the dialysate solution comprises up to 300 $\mu\text{mol/L}$ carnitine or the equivalent molar amount of a pharmaceutically acceptable salt thereof.

- 34 -

18. The method of claim 17 wherein the dialysate solution comprises up to 50 $\mu\text{mol/L}$ carnitine or the equivalent molar amount of a pharmaceutically acceptable salt thereof.
19. The method of claim 1 wherein the dialysate solution
5 comprises at least two nutrients selected from the group consisting of folic acid, vitamin B₆, thiamine, vitamin B₁₂, vitamin C, carnitine, and pharmaceutically acceptable salts thereof.
20. The method of claim 19 wherein the dialysate solution
10 comprises at least three nutrients selected from the group consisting of folic acid, vitamin B₆, thiamine, vitamin B₁₂, vitamin C, carnitine, and pharmaceutically acceptable salts thereof.
21. The method of claim 20 wherein the dialysate solution comprises folic acid, vitamin B₆, thiamine, vitamin B₁₂, vitamin C, and carnitine, or pharmaceutically acceptable salts thereof.
- 15 22. The method of claim 1 wherein the dialysis is peritoneal dialysis.
23. The method of claim 22 wherein the vitamin deficiency is prevented by adding at least a physiological amount of the vitamin to the dialysate solution.
- 20 24. The method of claim 22 wherein the vitamin deficiency is corrected by adding a supraphysiologic amount of the vitamin to the dialysate solution.
- 25 25. The method of claim 22 wherein the dialysate solution comprises up to 15 mg/L folic acid or the equivalent molar amount of a pharmaceutically acceptable salt thereof.

- 35 -

26. The method of claim 22 wherein the dialysate solution comprises up to 10 mg/L vitamin B₆ or the equivalent molar amount of a pharmaceutically acceptable salt thereof.

27. The method of claim 22 wherein the dialysate solution
5 comprises up to 7.5 mg/L thiamine or the equivalent molar amount of a pharmaceutically acceptable salt thereof.

28. The method of claim 22 wherein the dialysate solution comprises up to 1.0 mg/L vitamin B₁₂ or the equivalent molar amount of a pharmaceutically acceptable salt thereof.

29. The method of claim 22 wherein the dialysate solution further
10 comprises an effective amount of vitamin C or a pharmaceutically acceptable salt thereof.

30. The method of claim 29 wherein the dialysate solution
15 comprises up to 500 mg/L vitamin C or the equivalent molar amount of a pharmaceutically acceptable salt thereof.

31. The method of claim 22 wherein the dialysate solution further comprises an effective amount of carnitine or a pharmaceutically acceptable salt thereof.

32. The method of claim 31 wherein the dialysate solution
20 comprises up to 1 mmol/L carnitine or the equivalent molar amount of a pharmaceutically acceptable salt thereof.

33. The method of claim 22 wherein the dialysate solution comprises at least two nutrients selected from the group consisting of folic acid, vitamin B₆, thiamine, vitamin B₁₂, vitamin C, carnitine, and pharmaceutically
25 acceptable salts thereof.

- 36 -

34. The method of claim 33 wherein the dialysate solution comprises at least three nutrients selected from the group consisting of folic acid, vitamin B₆, thiamine, vitamin B₁₂, vitamin C, carnitine, and pharmaceutically acceptable salts thereof.

5 35. The method of claim 34 wherein the dialysate solution comprises folic acid, vitamin B₆, thiamine, vitamin B₁₂, vitamin C, and carnitine, or pharmaceutically acceptable salts thereof.

36. A dialysate solution comprising an effective amount of at least one vitamin selected from the group consisting of folic acid, vitamin B₆,
10 thiamine, vitamin B₁₂, and pharmaceutically acceptable salts thereof.

37. The dialysate solution of claim 36 further comprising an effective amount of vitamin C.

38. The dialysate solution of claim 36 further comprising an effective amount of carnitine.

15 39. The dialysate solution of one of claims 36-38 which is a hemodialysis solution.

40. The dialysate solution of one of claims 36-38 which is a peritoneal dialysis solution.

20 41. The dialysate solution of claim 36 comprising at least two nutrients selected from the group consisting of folic acid, vitamin B₆, thiamine, vitamin B₁₂, vitamin C, carnitine, and pharmaceutically acceptable salts thereof.

25 42. The dialysate solution of claim 41 wherein the dialysate solution comprises at least three nutrients selected from the group consisting of folic acid, vitamin B₆, thiamine, vitamin B₁₂, vitamin C, carnitine, and pharmaceutically acceptable salts thereof.

- 37 -

43. The dialysate solution of claim 42 wherein the dialysate solution comprises folic acid, vitamin B₆, thiamine, vitamin B₁₂, vitamin C, and carnitine, or pharmaceutically acceptable salts thereof.

5 44. A vitamin concentrate solution for use in a dialysate solution comprising at least one vitamin selected from the group consisting of folic acid, vitamin B₆, thiamine, vitamin B₁₂, and pharmaceutically acceptable salts thereof.

10 45. The vitamin concentrate solution of claim 44 comprising at least two nutrients selected from the group consisting of folic acid, vitamin B₆, thiamine, vitamin B₁₂, vitamin C, carnitine, and pharmaceutically acceptable salts thereof.

46. The vitamin concentrate solution of claim 45 comprising at least three nutrients selected from the group consisting of folic acid, vitamin B₆, thiamine, vitamin B₁₂, vitamin C, carnitine, and pharmaceutically acceptable salts thereof.

15 47. The vitamin concentrate solution of claim 46 comprising folic acid, vitamin B₆, thiamine, vitamin B₁₂, vitamin C, and carnitine, or pharmaceutically acceptable salts thereof.

48. The method of claim 1 wherein the dialysate solution further comprises at least one iron salt.

20 49. The method of claim 48 wherein the iron salt is ferric pyrophosphate.

50. The method of claim 1 wherein the dialysate solution further comprises at least one trace element selected from the group consisting of arsenic, rubidium, bromine, zinc, and pharmaceutically acceptable salts thereof.

25

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are stated below next to my name.

I believe I am the original, first, and sole inventor (if only one name is listed below) or an original, first, and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

TITLE OF INVENTION

DIALYSIS SOLUTIONS CONTAINING WATER SOLUBLE VITAMINS AND NUTRIENTS

the specification of which is attached hereto unless the following box is checked

☒ was filed on 6 August 1998 as Application Serial No. _____ or PCT Application No. PCT/US98/16383 and amended on ____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with 37 CFR §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed:

PRIOR FOREIGN/PCT APPLICATION(S)

COUNTRY/OFFICE	APPLICATION NO.	DATE OF FILING	PRIORITY CLAIMED
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

PROVISIONAL APPLICATION NUMBER	DATE OF FILING
60/055,015	7 August 1997

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) or §365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose material information as

defined in 37 CFR §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

**PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS
DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. §120**

Status (check one)

Application Serial No.	Date of Filing	Patented	Pending	Abandoned
_____	_____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
_____	_____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

And I hereby appoint Arthur H. Seidel, Registration No. ~~15,979~~; Gregory J. Lavorgna, Registration No. ~~30,469~~; Daniel A. Monaco, Registration No. ~~30,480~~; Thomas J. Durling, Registration No. ~~31,349~~; and John J. Marshall, Registration No. ~~29,671~~, my attorneys or agents with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

Address all correspondence to Seidel, Gonda, Lavorgna & Monaco, P.C., Suite 1800, Two Penn Center Plaza, Philadelphia, Pennsylvania 19102. Address all telephone calls to Daniel A. Monaco (215)568-8383 (telefax: 215-568-5549).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF SOLE OR FIRST INVENTOR

Ajay

(GIVEN NAME)

(MIDDLE INITIAL OR NAME)

Gupta

(FAMILY OR LAST NAME)

Inventor's signature: _____

Date: _____

August 24, 1999

Country of Citizenship: India

Residence: _____

Farmington Hills

Michigan

(City)

(State or Foreign Country)

Post Office Address: 39151 Horton, Farmington Hills, Michigan 48331